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Male androgen deficiency is an international health-related issue 
that has received increased attention over the past two decades, 
with considerable epidemiological evidence demonstrating a decline 
in testosterone levels with ageing.[1] The prevalence of androgen 
deficiency in middle-aged and older men was found to be between 
6% and 12% in the Massachusetts Male Aging Study.[2] Testosterone 
deficiency has been associated with a plethora of disorders including 
type 2 diabetes mellitus (T2DM), obesity, cardiovascular disease and 
the metabolic syndrome. The reported prevalence of low testosterone 
levels among men with T2DM is high and ranges between 30% 
and 50%.[3,4] The reason for the association between T2DM and 
low testosterone remains uncertain, but it has been postulated that 
a hypothalamic or pituitary cause is likely, given the predominant 
finding of normal or low luteinising hormone (LH) levels with low 
testosterone levels. [4] Evidence from meta-analyses has shown that 
T2DM is associated with lower total testosterone (TT) levels after 
adjusting for age and body mass index (BMI).[5] Despite the available 
evidence, current international diabetes guidelines do not advocate 
routine screening for testosterone levels in male patients with diabetes.
When assessing testosterone status, international guidelines 
advocate measuring TT, but recommend calculating free testosterone 
(FT) levels in patients with TT levels near the lower limit of the 
normal range or those in whom alterations of sex hormone-binding 
globulin (SHBG) are suspected.[3] A diagnosis of hypogonadism 
requires an unequivocally low testosterone level in conjunction 
with typical signs or symptoms of hypogonadism. A number of 
screening tools in the form of self-administered questionnaires have 
been developed, including the Ageing Males’ Symptom Scale (AMS) 
questionnaire, Massachusetts Male Aging Study questionnaire and 
Androgen Deficiency in the Ageing Male (ADAM) questionnaire.[6] 
However, none of these questionnaires have been validated in black 
African men.
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Background. The reported prevalence of low testosterone among men with type 2 diabetes mellitus (T2DM) is high. However, there is a 
dearth of information on the prevalence of androgen deficiency symptoms and low serum testosterone levels in men with T2DM from sub-
Saharan Africa. Scanty data are available from Nigeria, Ghana and South Africa (SA).
Objectives. To determine the prevalence of low serum testosterone and associated risk factors and the prevalence of androgen deficiency 
symptoms in men with T2DM.
Methods. In a cross-sectional observational study, androgen deficiency symptoms in men with T2DM attending two outpatient diabetes 
clinics in Durban, KwaZulu-Natal Province, SA, were assessed using the Ageing Males’ Symptoms Scale (AMS) questionnaire and direct 
enquiry. Serum total testosterone (TT), sex hormone-binding globulin (SHBG), luteinising hormone (LH), fructosamine, serum lipids and 
glycated haemoglobin (HbA1c) were measured and free testosterone (FT) was calculated. TT, SHBG and FT levels were measured in control 
subjects with no history of diabetes.
Results. There were 148 men with T2DM in the study group and 50 control subjects in the control group. In the study group, the majority 
were black Africans (58.8%); Indians (39.2%) and whites (2.0%) constituted the remainder. The mean (standard deviation (SD)) age was 
57.5 (11.2) years, the mean duration of diabetes 11.4 (8.9) years and the mean HbA1c 8.6% (1.9%). Of the study group, 85.8% had metabolic 
syndrome. Mean TT, SHBG and FT and median LH (interquartile range) in the study group were within normal ranges. However, mean 
(SD) serum TT and FT were lower in the study group than in the control subjects (14.5 (5.8) v. 18.8 (7.2) nmol/L; p<0.001 and 265.9 (90.4) v. 
351.7 (127.3) pmol/L; p<0.001, respectively). The prevalence of low serum total testosterone (LSTT) and low serum free testosterone (LSFT) 
in the study group was 35.8% and 16.2%, respectively. The prevalence of androgen deficiency symptoms using the AMS questionnaire was 
74.5% and correlated poorly with LSTT or LSFT. In multivariate analysis, LSFT was significantly associated with age (odds ratio (OR) 1.05, 
95% confidence interval (CI) 1.02 - 1.218; p=0.043) and waist circumference (WC) (OR 1.033, 95% CI 0.999 - 1.068; p=0.059). LSTT was 
associated with body mass index (BMI) only (OR 1.138, 95% CI 1.063 - 1.218; p<0.0001). TT correlated inversely with BMI, WC and the 
number of metabolic syndrome criteria. FT correlated inversely with BMI, WC and WHR.
Conclusions. There was a high prevalence of LSTT, LSFT and androgen deficiency symptoms in this study. Serum TT and FT were lower 
in men with T2DM than in control subjects. Risk factors associated with LSFT or LSTT included higher BMI and WC and older age. The 
AMS score was a poor predictor of low testosterone. More research is required locally before any screening policy can be recommended.
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There is a dearth of information on the prevalence of androgen 
deficiency symptoms and low serum testosterone levels in men with 
T2DM from sub-Saharan Africa (SSA). To date published data are 
available only from three countries, Nigeria, Ghana and South Africa 
(SA) (Table 1).[7-13] These studies report a high prevalence of low serum 
testosterone, from 29.5% to 50%. However, only a few studies have 
investigated the risk factors associated with low testosterone.[7,8,10,11]
Objectives
To determine the prevalence of and risk factors associated with 
low serum testosterone levels in men with T2DM attending two 
outpatient diabetes clinics in KwaZulu-Natal Province, SA.
Methods
This was a cross-sectional study undertaken at two hospitals in 
Durban. All males aged >18 years with a diagnosis of T2DM 
according to the World Health Organization definition[14] who were 
attending the adult diabetes clinic at Inkosi Albert Luthuli Central 
Hospital (IALCH) or the medical outpatient diabetes clinic at Prince 
Mshiyeni Memorial Hospital (PMMH) were invited to participate. 
Patients with diabetes classified as other than type 2 and those with 
disorders of sexual development were excluded. Healthy adult men 
employed at IALCH and PMMH or relatives of patients attending the 
diabetes clinic were recruited as control subjects. Control subjects 
were excluded if they had a history of glucose intolerance, low 
testosterone or disorder of sexual development. Informed consent 
was obtained from all subjects.
At study entry, a detailed history was obtained from all study 
subjects by questionnaire and patient folder review. Information 
collected included demographic details, symptoms of androgen 
deficiency, smoking history, current drug therapy, past medical 
history, and microvascular or macrovascular diabetes complications. 
Symptoms of androgen deficiency were assessed via direct patient 
enquiry (change in growth of facial hair/beard growth; loss of libido; 
erectile dysfunction) and with the AMS questionnaire.[6] The AMS 
questionnaire includes three subcategories consisting of a defined 
set of items, and each question is rated on a scale of 1 - 5 points. 
Patients with an AMS score of <27 were classified as having few or no 
symptoms. A score of 27 - 36 was graded as mild symptoms, 37 - 49 as 
moderate and ≥50 as severe. Anthropometric measurements (weight, 
height, and waist and hip circumference) and blood pressure were 
recorded on the day of serum testosterone sample collection.
Laboratory tests performed on all study subjects included serum 
TT, SHBG, LH, serum lipids (Advia 1800 Clinical Chemistry 
System; Siemens, Germany), glycated haemoglobin (HbA1c) 
(G8  HPLC Analyser; Tosoh Bioscience, USA) and serum fructo-
samine (Dimension EXL 200 Integrated Chemistry System; 
Siemens, Germany). FT was calculated using the Vermeulen 
equation. Venous blood samples were collected between 08h00 and 
10h00 from a forearm vein. Specimens for LH, SHBG and TT were 
centrifuged and the plasma was stored at –70oC until analysed as a 
single batch.
Low serum total testosterone (LSTT) was defined as a measured 
serum TT <12.0 nmol/L.[15] Low serum free testosterone (LSFT) 
was defined as a calculated FT <180 pmol/L (reference range 180 - 
739 pmol/L). Using FT as the criterion, hypogonadism was defined as 
LSFT <180 pmol/L and an AMS score ≥27. Using TT as the criterion, 
hypogonadism was defined as LSTT <12 nmol/L[15] and an AMS 
score ≥27. Overt hypogonadism was defined as TT <8 nmol/L and 
an AMS score ≥27. LH levels between 3.8 mIU/L and 7.3 mIU/L were 
classified as normal, levels <3.8 mIU/L as low and levels >7.3 mIU/L 
as high. Metabolic syndrome was defined by the criteria of the Joint 
Interim Statement of the International Diabetes Federation Task 
Force on Epidemiology and Prevention.[16]
The sample size was calculated using an open-source calculator 
(OpenEpi, version 3; Open Source Epidemiologic Statistics for 
Public Health, www.OpenEpi.com). The study aimed to recruit an 
equal number of cases and controls and with power set at 80%, a 
hypothetical proportion of controls with exposure at 10% and a 
hypothetical proportion of cases with exposure at 33% (using data 
Table 1. Studies on the prevalence of low serum testosterone in T2DM patients from sub-Saharan Africa
Country, author/s Study group N
Age (years), mean 
(SD)
Serum TT 
(nmol/L), mean 
(SD) p-value
Definition 
of LSTT 
(nmol/L)
Prevalence of 
LSTT, %
South Africa
Kemp and Rheeder[7] DM* 150 62.0 (7.9) 9.88 (7.0 - 14.1)† - <9.9 50
Ghana
Asare-anane et al.[8] T2DM
Control
105
105
48.9 (9.4)
42.8 (5.6)
10.8 (5.0)
15.6 (3.9)
0.00018 <12 55.2
Nigeria
Ogbera[9] T2DM 203 61 (30 - 85)† 7.9 (3.2) - <12‡ 36
Ugwu et al.[10] T2DM 200 57.9 (8.7) 14.3 (7.9) - <12 53¶
Akinloye et al.[11] T2DM§
Control
49
34
63.8 (1.5)
59.7 (2.6)
3.1 (0.34)
34.0 (3.9)
<0.0001 - -
Ubajaka et al.[12] T2DM
Control
125
50
-
-
13.5 (6.5)
17.6 (5.8)
<0.05 - -
Fabian et al.[13] T2DM
Control
34
53
63.6 (2.0)
37.9 (1.7)
27.0 (3.0)
32.6 (2.5)
0.01 - -
T2DM = type 2 diabetes mellitus; SD = standard deviation; TT = total testosterone; LSTT = low serum total testosterone; DM = diabetes mellitus; IQR = interquartile range.
*T2DM in 91% of the cohort.
†Median (IQR).
‡TT 8 - 12 nmol/L with symptoms of hypogonadism or TT <8 nmol/L with or without symptoms of hypogonadism.
§Newly diagnosed T2DM.
¶Prevalence 29.5% if LSTT defined as <8 nmol/L.
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from the literature), the required number of cases was 49 and that 
of control subjects 49. The study was approved by the University 
of KwaZulu-Natal Biomedical Research Ethics Committee (ref. no. 
BF 225/13) and the KwaZulu-Natal Department of Health (ref. no. 
HRKM 322/13).
Statistical analysis
The Statistical Package for the Social Sciences (SPSS) version 23 
(IBM, USA) was used for data analysis. Descriptive analysis of the 
data was performed (means, standard deviations (SDs), ranges, 
frequencies and percentages). Independent t-tests were used to 
compare continuous normal variables between binary groups. 
Pearson’s χ2 tests were used to compare categorical variables between 
groups. Missing continuous data were replaced by the series mean. 
Univariate logistic regression analysis was used to screen all risk 
factors at the 0.1 level of significance for inclusion into a multiple 
logistic regression model. Once predictors were chosen, they were 
entered into a backwards stepwise model with entry and exit 
probabilities set at 0.05 and 0.1, respectively.
Results
The total study population for analysis comprised 148 male subjects 
with T2DM (study group) and 50 control subjects (control group), 
recruited between January 2014 and March 2015. Of 157 patients 
who consented to participate in the study, 97 were recruited at IALCH 
and 60 at PMMH; 9 were excluded because of known hypothalamic 
or pituitary disease. Table 2 shows the characteristics of the study 
group. The mean (SD) age was 57.5 (11.2) years. The majority were 
black African (58.8%, n=87), followed by Indian (39.2%, n=58); white 
patients were in the minority, constituting only 2.0% (n=3) of the 
Table 2. Characteristics of the study group (N=148)
Demographic data
Age (years), mean (SD) 57.5 (11.2)
Ethnicity, n (%)
Black African 87 (58.8)
Indian 58 (39.2)
White 3 (2.0)
Diabetes duration (years), mean (SD) 11.4 (8.9)
Smoking (current or ex), n (%) 55 (37.2)*
Prevalence of diabetes complications, n (%)
Retinopathy 35 (23.6)
Microalbuminuria 34 (22.9)
Proteinuria 27 (18.2)
IHD 26 (17.6)
PVD 11 (7.4)
CVD 6 (4.1)
Anthropometry, mean (SD)
Height (cm) 170.0 (0.06)
Weight (kg) 85.9 (17.8)
BMI (kg/m2) 29.8 (6.0)
Waist circumference (cm) 103.3 (12.9)
Medication history (N=140), n (%)
Metformin 100 (71.4)
Sulphonylurea† 44 (31.4)
DPP4i 2 (1.4)
Insulin‡ 78 (55.7)
Statin 92 (65.7)
Fibrate 5 (3.6)
Antihypertensive§ 117 (83.6)
Aspirin 93 (66.4)
Metabolic profile
HbA1c (%) (N=145), mean (SD) 8.6 (1.9)
Serum fructosamine (µmol/L) (N=88), mean (SD) 317.5 (71.7)
Serum lipids (mmol/L) (N=128)
TC, mean (SD) 4.2 (1.3)
TG, median (IQR) 1.7 (1.1 - 2.7)
HDLC, mean (SD) 1.1 (0.3)
LDLC, mean (SD) 2.5 (1.41)
SD = standard deviation; IQR = interquartile range; IHD = ischaemic heart disease; PVD = peripheral vascular disease; CVD = cerebrovascular disease; BMI = body mass index; DPP4i = dipeptidyl-
peptidase 4 inhibitor; HbA1c = glycated haemoglobin; TC = total cholesterol; TG = total triglycerides; HDLC = high-density lipoprotein cholesterol; LDLC = low-density lipoprotein cholesterol.
*Median pack-years of smoking 9 years (IQR 0.5 - 60).
†Gliclazide 21.5%, glibenclamide 9.3%.
‡Median dose 56 IU/d.
§Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker 68.6%, diuretic 59.3%, amlodipine 41.4%, doxazocin 13.6%, beta-blocker 21.4% (some patients used more than one agent). 
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study population. The mean (SD) duration 
of diabetes was 11.4 (8.9) years with 46.3% of 
the group having had T2DM for >10 years. 
The majority (81.8%) of the patients were 
overweight or obese, and 85.8% fulfilled 
the criteria for metabolic syndrome. The 
microvascular complications of retinopathy, 
microalbuminuria and proteinuria were 
noted in 23.6%, 22.9% and 18.2% of patients, 
respectively. The prevalence of known 
ischaemic heart disease (IHD), peripheral 
vascular disease (PVD) and cerebrovascular 
disease (CVD) was 17.6%, 7.4% and 4.1%, 
respectively.
The mean (SD) HbA1c in the study 
group was 8.6% (1.9%), mean serum total 
cholesterol 4.2 (1.3) mmol/L and mean 
serum low-density cholesterol 2.5 (1.41) 
mmol/L (Table 2). Mean serum FT levels 
were significantly lower with increasing age 
and higher BMI (Figs 1 and 2). Mean FT 
was lowest in the >40 kg/m2 category and 
significantly lower when compared with all 
other BMI categories (v. <25 kg/m2 p<0.001; 
v. 25 - 29.9 kg/m2 p<0.0001; v. 30 - 39.9 kg/
m2 p<0.05).
When compared with the control group, 
the study group (T2DM) was significantly 
older (mean (SD) 57.7 (11.1) v. 43.9 (10.7) 
years; p<0.001) and had a higher BMI (29.8 
(6) v. 27.1 (4.2) kg/m2; p=0.01). Mean (SD) 
serum TT (14.5 (5.8) v. 18.8 (7.2) nmol/L; 
p<0.001) and FT (265.9 (90.4) v. 351.7 
(127.3)  pmol/L; p<0.001) were significantly 
lower in the study group, while the prevalence 
of LSTT and LSFT was significantly higher 
in the study group (p=0.0087 and p=0.0088, 
respectively) (Table 3). In logistic regression 
analysis, FT remained significantly lower 
in the study group v. the control subjects 
(p=0.001) after adjusting for other variables 
such as age and BMI (Table 4).
In the study group, the prevalence of 
androgen deficiency symptoms was higher 
using the AMS questionnaire (74.5%) (mild 
36.2%, moderate 26.9%, severe 11.4%) 
compared with direct patient enquiry 
(68.9%), although this difference was not 
statistically significant. The most common 
symptom on direct enquiry was erectile 
dysfunction (58.8%); loss of libido, decrease 
in beard growth and infertility were reported 
in 56.1%, 2.7% and 2.0%, respectively 
(Table 5, Fig. 3).
The prevalence of LSFT was 16.2%, and 
it rose significantly with increasing age and 
BMI. The prevalence of LSTT was 35.8%; 
however, with a more stringent cut-point 
of <8 nmol/L, the prevalence was 10.1%. 
Hypogonadism was present in 11.5% using 
FT and in 26.3% using TT <12 nmol/L. 
Using TT <8 nmol/L and an AMS score ≥27, 
overt hypogonadism was observed in 7.4% 
(Table 5).
In univariate analysis, LSFT was associated 
with age, a decrease in beard growth, BMI, 
waist circumference (WC), hip circumference 
and albumin level. In multivariate analysis, 
the significant independent risk factors 
associated with LSFT were age (odds ratio 
(OR) 1.05, 95% confidence interval (CI) 
1.02 - 1.218; p=0.043) and WC (OR 1.033, 
95% CI 0.999 - 1.068; p=0.059). LSTT 
was associated with microalbuminuria, 
proteinuria, weight, BMI, WC, hip circum-
ference and metabolic syndrome on uni-
variate analysis. In multivariate analysis, 
the only significant independent risk factor 
associated with LSTT was BMI (OR 1.138, 
95% CI 1.063 - 1.218; p<0.0001).
There was no significant difference in 
the total or individual domain AMS 
questionnaire scores between patients with 
LSFT and those with normal FT. Receiver 
operating characteristic curve analysis 
showed that the AMS score was not a good 
predictor of LSFT or LSTT (area under the 
curve 0.5 (95% CI 0.37 - 0.64) and 0.49 (95% 
CI 0.39 - 0.59), respectively). There was a 
poor correlation between TT or FT and the 
AMS scores (r=0.1, p=0.3; r=–0.003, p=0.9, 
respectively).
A moderate inverse correlation was found 
between TT and BMI as well as WC (r=–0.34, 
p<0.001; r=–0.35, p<0.001, respectively). 
500
400
300
200
100
0
p<0.05
Age group (years)
p<0.05
 p=NS
p<0.05
Fr
ee
 te
st
os
te
ro
ne
 (p
m
ol
/L
)
<40                  40 - 49                   50 - 59                   60 - 69                     ≥70
Fig. 1. Serum free testosterone in men with type 2 diabetes, by age (N=148). (NS = not significant.)
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Fig. 2. Mean serum free testosterone across BMI categories in men with type 2 diabetes (N=148).  
(NS = not significant; BMI = body mass index.)
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Regarding FT, a moderate inverse correlation 
with age and WC (r=–0.45, p<0.001; r=–0.33, 
p<0.001) was noted. The scatter plot in Fig. 4 
shows the negative correlation of FT with 
BMI and weight (r=–0.27, p<0.001; r=–0.21, 
p<0.01, respectively). For both FT and TT, 
no significant correlation was observed with 
HbA1c.
Mean (SD) serum LH levels were 
significantly lower in the control group 
than in the study group (4.5 (2.3) IU/L v. 
5.8 (3.1) IU/L; p=0.006), but levels were 
within the normal range for both groups. The 
majority of patients with LSTT or LSFT had 
low or normal LH levels (79.2% and 81.1%, 
respectively), compatible with secondary 
hypogonadism; the remainder (20.8% and 
18.9%, respectively) had a high LH level 
compatible with primary hypogonadism 
(Table 3).
Discussion
This study showed a high prevalence of 
LSFT and LSTT in men with T2DM. The 
prevalence of androgen deficiency symptoms 
was high using either the AMS questionnaire 
or direct enquiry. The AMS questionnaire 
was found to be a poor predictor of low 
serum testosterone, and there was a weak 
correlation between AMS scores and serum 
testosterone. LH levels were either normal 
or low in the majority of patients with LSFT 
or LSTT, compatible with hypogonadotropic 
hypogonadism. In multivariate analysis, there 
was an independent negative association 
with age and WC in diabetic men with LSFT.
The high prevalence of low serum 
testosterone observed in this study is in 
accordance with the reported prevalence 
(17 - 33%) from cross-sectional studies 
in Western countries such as the USA.[4,17] 
Similarly high prevalences have also been 
reported from India (26.3%), Jordan (36.5%) 
and Poland (46%).[18-20] Furthermore, the 
observation of significantly lower TT and 
FT in the diabetic men compared with 
the control subjects is compatible with the 
findings of a large meta-analysis.[5]
Table 4. Logistic regression analysis for risk factors associated with low serum free 
testosterone in the study group v. the control group
OR SE 95% CI p-value
Age 1.130 0.023 1.081 - 1.182 <0.0001
BMI 1.094 0.050 0.992 - 1.206 0.071
OR = odds ratio; SE = standard error; CI = confidence interval; BMI = body mass index.
Table 3. Clinical characteristics, biochemical results and prevalence of low serum testosterone in the study group compared with 
the control group
Study group (N=148) Control group (N=50) p-value
Clinical characteristics, mean (SD)
Age (years) 57.7 (11.1) 43.9 (10.7) <0.001
BMI (kg/m2) 29.8 (6.0) 27.1 (4.2) 0.011
Systolic BP (mmHg) 136 (16.5) 130.9 (21.6) 0.134
Diastolic BP (mmHg) 77.3 (10.0) 76.4 (8.6) 0.613
Hormonal profile, mean (SD)
Total testosterone (nmol/L) 14.5 (5.8) 18.8 (7.2) <0.001
SHBG (nmol/L) 40.7 (20.3) 42.0 (20.0) 0.685
Free androgen index 40.4 (17.0) 49.6 (19.5) 0.002
Free testosterone (pmol/L) 265.9 (90.4) 351.7 (127.3) <0.001
LH (IU/L) 5.8 (3.1) 4.5 (2.3) 0.006
Prevalence of low serum testosterone, % (95% CI)
LSTT 35.8 (28.5 - 43.8) 16.0 (8.3 - 28.5) 0.0087
LSFT 16.2 (11.2 - 23.0) 2.0 (0.35 - 10.5) 0.0088
Prevalence of low or normal LH, % (95% CI) 
LSTT (N=53) 81.1 (68.6 - 89.4) - -
LSFT (N=24) 79.2 (59.5 - 90.7) - -
SD = standard deviation; CI = confidence interval; BMI = body mass index; BP = blood pressure; SHBG = sex hormone-binding globulin; LH = luteinising hormone; LSTT = low serum total 
testosterone; LSFT = low serum free testosterone.
71.4
90
80
70
60
50
40
30
20
10
0
*<40 v. 50 - 59-year age group, p<0.05; <40 v. 60 - 69-year age group, p<0.01
<40                     40 - 49                  50 - 59                 60 - 69                    ≥70
A
M
S 
≥2
7,
 %
Age group (years)
37.5*
66.6
79.1
 83.7
Fig. 3. Prevalence of a positive AMS score (≥27) across age groups in men with type 2 diabetes (N=148). 
(AMS = Ageing Males’ Symptoms Scale.)
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There are limited data on the prevalence 
of low serum testosterone in men with 
T2DM from SSA, with only a few studies 
from Nigeria and a single study each from 
Ghana and SA.[7-13] Such studies report 
the prevalence of LSTT as 29.5 - 55%.[7-10] 
Compared with the present study, Kemp and 
Rheeder[7] reported a higher prevalence of 
LSTT (50%) in 150 men attending a tertiary 
diabetes clinic in Pretoria, the majority of 
whom (91%) had T2DM. This finding could 
be related to the characteristics of the study 
population, who were older than our subjects 
(62 v. 57.5 years) and had a longer duration 
of diabetes (15 v. 11.4 years), a higher mean 
WC (112 v. 103 cm) and a higher burden 
of CVD (41% v. 18%). A finding common 
to the Pretoria study and the present study 
was the strong association between WC and 
LSTT.
Screening for symptoms of androgen 
deficiency has been recommended by some 
organisations to justify measurement of 
serum testosterone.[21] The few available 
studies in diabetic men have shown that 
the sensitivity of using questionnaires 
is high, but that they lack specificity; 
also, they correlate poorly with serum 
testosterone, similar to the findings of the 
present study. [19,22,23] The Pretoria study[7] 
found that the ADAM questionnaire had a 
high sensitivity (95%) and low specificity 
(5%), similar to the findings of a cross-
sectional survey among 200 Nigerian men 
with T2DM.[7,24] The value of the AMS and 
ADAM questionnaires in SSA populations 
therefore remains unresolved, and they 
require further validation before they can 
be recommended in routine practice. Direct 
patient enquiry for symptoms such as loss 
of libido and erectile dysfunction should be 
considered.
From the available literature, the 
prevalence of hypogonadism among men 
with T2DM in Western countries ranges 
from 20% to 42%.[17,25] The prevalence of 
11.5% in the present study (defined as LSFT 
with a positive AMS score) is lower than that 
reported in three studies from Nigeria (29.5 - 
65.3%), and is probably related to differences 
in the definition of hypogonadism used 
in these studies.[9-11] It is well recognised 
that the majority of diabetic men with low 
serum testosterone have normal or low 
Table 5. Prevalence of androgen deficiency symptoms, low serum testosterone and hypogonadism in the study group (N=148)
n (%) 95% CI
Symptoms on enquiry*
Any symptom 102 (68.9) 61.1 - 75.8
Erectile dysfunction 87 (58.8) 50.7 - 66.4
Low libido 83 (56.1) 48.0 - 63.8
Decrease in beard growth 4 (2.7) 1.1 - 6.7
Infertility 3 (2.0) 0.7 - 5.8
AMS questionnaire score
≥27 111 (75.0) 67.5 - 81.2
27 - 36 (mild) 54 (36.2) 29.1 - 44.5
37 - 49 (moderate) 40 (26.9) 20.5 - 34.7
>49 (severe) 17 (11.4) 7.3 - 17.6
Prevalence of low serum testosterone
LSFT (<180 pmol/L) 24 (16.2) 11.1 - 23.0
LSTT (<12 nmol/L) 53 (35.8) 28.5 - 43.8
LSTT (<8 nmol/L) 15 (10.1) 6.2 - 16.1
Prevalence of hypogonadism†
FT <180 pmol/L + AMS score ≥27 17 (11.5) 7.3 - 17.6
TT <12 nmol/L + AMS score ≥27 39 (26.3) 19.9 - 33.9
TT <8 nmol/L + AMS score ≥27‡ 11 (7.4) 4.2 - 12.8
AMS = Ageing Males’ Symptoms Scale; LSFT = low serum free testosterone; LSTT = low serum total testosterone; FT = free testosterone; TT = total testosterone.
*Some patients reported more than one symptom.
†Hypogonadism was defined as LSFT <180 pmol/L and an AMS score ≥27 or LSTT <12 nmol/L and an AMS score ≥27.
‡Overt hypogonadism was defined as TT <8 nmol/L and an AMS score ≥27.
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Fig. 4. Relationship between free testosterone and BMI and weight in men with type 2 diabetes (N=148). 
(BMI = body mass index.)
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levels of LH (67 - 83%), and the findings of the present study are 
compatible with these reports.[4,17,19,26,27] These findings suggest that 
the majority of men with low testosterone have features compatible 
with hypogonadotropic hypogonadism as the underlying defect.
The significant risk factors associated with LSFT and LSTT 
in the present study were WC and BMI, similar to reports from 
other studies.[28,29] Although lower SHBG concentrations related 
to higher obesity levels in diabetics may partly explain the lower 
TT, they do not account for the lower FT levels. Other factors such 
as elevated circulating adipokines or higher oestradiol levels may 
explain the effect in men with diabetes owing to the association of 
this disease with obesity.[30,31] T2DM in itself is an inflammatory 
state that may suppress gonadotropin-releasing hormone (GnRH). 
However, the hypogonadal-obesity-adipokine hypothesis implicates 
the proinflammatory adipokines elaborated by adipose tissue depots 
as the inciting agents that suppress GnRH secretion, thus lowering 
testosterone synthesis.[32] Of particular concern for SSA are rising 
obesity rates, especially in SA, which has the highest prevalence of 
obesity, because many more men will be at risk of developing low 
testosterone and the consequences thereof.[33]
The effect of ageing on lowering testosterone levels among men in 
the general population has clearly been shown in landmark studies. [1,2] 
In an SA cohort of the Transition and Health during Urbanisation of 
South Africans (THUSA) study that investigated 364  male subjects 
between the ages of 20 and 82 years, testosterone levels also declined 
with age.[34] This finding was supported by the present study, but of 
note was the absence of LSFT among all patients aged <40 years. 
If screening for androgen deficiency is being considered in this 
population, routinely screening patients aged <40 years may not be 
cost-effective.
No association between serum testosterone and HbA1c was 
noted in our cohort, similar to findings in other studies.[4,7,8,10,29] 
Although we observed no association between serum lipids and 
serum testosterone, there was a weak inverse correlation between 
serum TT and serum total triglycerides, similar to two other studies 
from SSA.[8,11]
Current international guidelines recommend screening men with 
T2DM for low testosterone.[3] The SA guideline for the management 
of T2DM published by the Society for Endocrinology Metabolism 
and Diabetes of South Africa (SEMDSA) in 2017 states that 
screening for low serum testosterone levels in men with T2DM and 
symptoms of hypogonadism is mandatory.[21] The available evidence 
suggests that screening may be justified in this high-risk population 
and that men most likely to benefit from screening would be older 
and overweight with predominant central adiposity. Furthermore, 
appropriate treatment in the form of testosterone replacement 
is available. More local data are required, including cost-benefit 
analysis, before recommendations can be made regarding a 
screening policy for SA men with T2DM. The poor performance 
of the ADAM and AMS questionnaires highlights the need for 
further studies to validate their use. Alternatively, direct enquiry 
into symptoms such as erectile dysfunction and loss of libido can 
be considered.
Study limitations and strengths
The major limitations of this study were its cross-sectional design 
and the small sample of white men. Although IHD, PVD and 
CVD may be associated with hypogonadism, statistical analysis to 
control for these variables was not done. Study strengths include the 
measurement of both FT and TT and inclusion of men from district-
level and tertiary-level clinics.
Conclusions
There was a high prevalence of low serum TT and FT in this study. 
Serum testosterone was lower in men with T2DM than in control 
subjects. Risk factors associated with low serum testosterone included 
older age and higher BMI and WC. The prevalence of androgen 
deficiency symptoms was high, but the AMS score was a poor 
predictor of low testosterone. Screening may be justifiable in this 
population, but further research is required locally to conduct a cost-
benefit analysis before any policy can be advocated.
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